The incidence and short-term outcome of anaemia in inflammatory bowel disease ( IBD ) are largely unknown.
A study has attempted to determine the incidence, prevalence and clinical outcome of anaemia in terms of resolution of anaemia within 12 months.
Researchers have also planned to assess risk factors for anaemia in inflammatory bowel disease.
A random sample of 342 patients was obtained from the population-based IBD cohort of Örebro University Hospital, Sweden, consisting of 1405 patients diagnosed between 1963 and 2010.
In Crohn's disease, the incidence rate of anaemia was 19.3 ( 95% CI: 15.4-23.7 ) per 100 person-years and the prevalence was 28.7% ( CI: 22.0-36.2 ), compared with 12.9 ( CI: 9.8-16.5 ) and 16.5% ( CI: 11.2-22.9 ) for ulcerative colitis.
Crohn's disease was associated with an increased incidence ( odds ratio, OR = 1.60; CI: 1.02-2.51 ) and prevalence of anaemia ( OR = 2.04; CI: 1.20-3.46 ) compared to ulcerative colitis.
Stricturing disease phenotype in Crohn's disease ( hazard ratio, HR = 2.59; CI: 1.00-6.79 ) and extensive disease in ulcerative colitis ( HR = 2.40; CI: 1.10-5.36 ) were associated with an increased risk of anaemia.
Despite a higher probability of receiving specific therapy within 3 months from the diagnosis of anaemia, Crohn's disease patients had a worse outcome in terms of resolution of anaemia within 12 months ( 56% vs 75%; P = 0.03 ).
In conclusion, anaemia is a common manifestation of inflammatory bowel disease even beyond the first years after the diagnosis of inflammatory bowel disease.
Crohn's disease is associated with both an increased risk and a worse outcome. ( Xagena )
Eriksson C et al, Aliment Pharmacol Ther 2018; Epub ahead of print